Frontiers in Cross-Protective Vaccines
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 4980
Special Issue Editors
Interests: coronaviruses; viral enteritis; respiratory and genital diseases
Special Issues, Collections and Topics in MDPI journals
Interests: blood parasite; transmission blocking vaccine; Babesia; Transfection; vector born diseases; ticks; genetic markers; vaccines
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Inclusion of cross-protective antigens is usually considered desirable when developing vaccines against different pathogens of several species and may also be important from a public health perspective. In this Special Issue, we encourage our colleagues to search within the abundant data available from all “omics” and other resources towards identifying promising cross-reactive antigens for vaccine development. Such vaccines may include single or multiple cross-reactive antigens and may help to prevent unpredictable homologous and heterologous infections. It is expected that this novel vaccine development approach will have a major impact in the context of disease prevention, while also having economic and practical advantages. We welcome your interesting research or review article covering these topics in our current Special Issue titled “Frontiers in Cross-Protective Vaccines”.
Prof. Dr. Maria Tempesta
Dr. Heba Alzan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- conserved epitope
- cross protection
- vaccine
- heterogenicity
- homology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
